Background
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) being studied for HIV-1 treatment. Exposure-related decreases in total lymphocyte and CD4+ T-cell counts were observed across ISL clinical trials, with greater changes observed in ISL higher-dose regimens. Models that describe changes in lymphocytes and CD4+ T-cells in relation to intracellular ISL-triphosphate (TP) concentrations were used to optimize the QW dose for HIV treatment. ISL 2 mg QW was predicted to achieve efficacy thresholds and similar lymphocyte and CD4+ T-cell dynamics compared to standard antiretroviral therapy (ART). Subsequently, a Phase 2 study was initiated (GS-US-563-6041, N=104) with virologically suppressed (VS) people with HIV-1 randomized 1:1 to switch from once-daily (QD) oral bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) to oral QW ISL 2 mg + lenacapavir (LEN) 300 mg.
Methods
Simulations were performed using a previously developed ISL PopPK model, with observed ISL plasma PK for Phase 2 participants as input, to predict ISL-TP exposures in Phase 2 participants. Previously developed ISL PK/PD models were used to simulate lymphocyte and CD4+ T cell counts using PopPK-predicted ISL-TP exposures for Phase 2 participants as input.
Results
Observed ISL plasma PK exposures for Phase 2 participants were consistent with exposures predicted for 2 mg QW in simulations performed prior to the Phase 2 study (Figure 1A). Simulations performed using the ISL PopPK model with observed ISL plasma PK for Phase 2 participants as input demonstrated that all Phase 2 participants achieved ISL-TP exposures above the inhibitory quotient (IQ)5 (1.25 µM) for M184V/I variants and IQ5 (0.25 µM) for wild-type (WT) HIV-1 (Figure 1B). As predicted, achieving these exposures resulted in high rates of participants maintaining virologic suppression through Week 24 in the Phase 2 study. ISL-TP exposures achieved in Phase 2 were below levels predicted by the PK/PD models to have lymphocyte and CD4+ T cell effects. No between-group differences in lymphocyte and CD4+ T cell changes were observed in Phase 2.
Conclusions
Phase 2 efficacy and lymphocyte and CD4+ T-cell results are consistent with predictions that QW 2 mg ISL in combination with LEN is highly efficacious and there were no between-group differences in lymphocyte or CD4+ T-cell changes from baseline to Week 24. ISL/LEN 2/300 mg is proceeding into Phase 3 with the potential to be the first oral QW treatment option.
Table or Figure
![]()